Dr. Anna Berry is Vice President, Molecular Pathology and Genomics at Syapse, where she is working with real world evidence and genomic data to accelerate and improve precision oncology and quality patient care. Previously, she was Deputy Director for Molecular Pathology and Genomics at the Swedish Cancer Institute, where she also served as the Scientific Director of the Personalized Medicine Program, which she was instrumental in launching. Prior to her time at Swedish, Dr. Berry served on the faculty at UCSF for nearly a decade, during which she served as the inaugural director of the Molecular Pathology Clinical Laboratory, and also as the inaugural director of the Molecular Genetic Pathology fellowship. Dr. Berry is a graduate of the University of Nebraska Medical Center, and completed her post-graduate training at SUNY Upstate Medical University, the Medical College of Virginia, and the National Cancer Institute. She is Board Certified in Molecular Genetic Pathology, Cytopathology, Anatomic Pathology and Clinical Pathology. She serves on several national committees, including the Personalized Healthcare Committee of the College of American Pathologists, and participates in several national genomics task forces. She has also contributed to many peer-reviewed publications, and has given numerous invited lectures.